Gainesville, FLNCT07569263Now EnrollingIRB Ready

Brain Metastases Clinical Trial in Gainesville, FL

Access cutting-edge brain metastases treatment through this phase 1 clinical trial at a research site in Gainesville. Study-provided care at no cost to qualified participants.

Sponsored by University of Florida

Quick Self-Assessment

See if you qualify for this Gainesville location

Preparing your pre-screening questions…

Expert Care in Gainesville

Access brain metastases specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related brain metastases treatment provided free

Apply for This Gainesville Location

Check if you qualify for this brain metastases clinical trial in Gainesville, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Gainesville

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Gainesville site if eligible
  4. 4Begin participation

About This Brain Metastases Study in Gainesville

This is a Phase I Study evaluating the safety and feasibility of IL-8 receptor-modified patient-derived activated CD70 CAR T cells in adult patients with brain metastases from primary cancer, with either newly diagnosed lesions or recurrent or progressive disease after prior therapy.

Sponsor: University of Florida

Who Can Participate

Inclusion Criteria

Histological confirmation of primary cancers
Histologic confirmation of CD70 on primary tumor, lymph node, or BM biopsy CD70-positive tumor expression confirmed by the investigational CD70 IHC assay defined as CD70 immunoreactivity in ≥ 5% of tumor cells at any staining intensity.
At least one recurrent or progressive metastatic lesion or new metastatic lesion(s).
18 years or older.
Adequate bone marrow and organ function as defined below:
CBC with differential with adequate bone marrow function as defined below:
Absolute neutrophil count (ANC) ≥ 1000 cells/mm3.
Platelet count ≥ 75,000 cells/mm3.
Hemoglobin ≥ 9 g/dl. (use of transfusion or other intervention to achieve Hgb ≥ 9 g/dl is acceptable.)
Adequate renal function as defined below:
BUN ≤ 25 mg/dl
Creatinine ≤ 1.7 mg/dl
Adequate hepatic function as defined below:
Bilirubin ≤ 2.0 mg/dl
ALT ≤ 5 times institutional upper limits of normal for age
AST ≤ 5 times institutional upper limits of normal for age
A diagnostic contrast-enhanced brain MRI must be performed within 28 days prior to study enrollment.
For females of childbearing potential, a negative serum pregnancy test at enrollment.
Women of childbearing potential (WOCBP) must be willing to use an acceptable contraceptive method to avoid pregnancy throughout the study and for at least 24 weeks after the last dose of study drug.
Males with female partners of childbearing potential must agree to practice adequate contraceptive methods throughout the study and should avoid conceiving children for 24 weeks following the last dose of the study drug.
Ability of the patient to understand and willingness to sign an IRB approved written informed consent document.
Steroid dose equivalent to dexamethasone dose of ≤ 6mg daily at the time of enrollment.
Patients treated on any other investigational therapy must discontinue that treatment prior to study entry.

Exclusion Criteria

• Known immunosuppressive disease or human immunodeficiency virus (HIV) infection. Rationale: The need to exclude patients with an immunosuppressive disease or human immunodeficiency virus infection is necessary because the management of potential toxicities from the study drug may involve treatment that is significantly immunosuppressive.
Participant has ongoing toxicity ≥ grade 2 per the CTCAE version 5.0 considered clinically significant and in the opinion of the investigator, attributable to prior antineoplastic therapies.
Participant has received any chemotherapy or other immunotherapy within 14 days prior to the first dose of study intervention.
Severe, active co-morbidity, defined as follows:
Unstable angina and/or congestive heart failure requiring hospitalization.
Transmural myocardial infarction within the last 6 months.
Acute bacterial or fungal infection requiring intravenous antibiotics.
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization.
Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
Patients with an autoimmune disease requiring medical management with immunosuppressants.
Major medical illnesses or psychiatric impairments that, in the investigator's opinion, will prevent administration or completion of protocol therapy.
Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Gainesville?

Yes, this clinical trial (NCT07569263) has an active research site in Gainesville, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Brain Metastases Treatment Options in Gainesville, FL

If you're searching for brain metastases treatment options in Gainesville, FL, this clinical trial (NCT07569263) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Gainesville research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced brain metastases specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all brain metastases clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Gainesville, FL

See all brain cancer clinical trials recruiting in Gainesville — not just this study.

Browse Brain Cancer Trials in Gainesville →

Browse More Trials by Condition

Brain Cancer TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Gainesville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Gainesville, FL